Roberto A Novoa, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Novoa’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A131200 · Current
Licensed to practise in California · since 2014 · expires 2027-12-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$208,201
Medicare paid this office $208,201 for 2,274 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 1,827 | $93,618 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 306 | $18,104 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 419 | $17,438 | $30 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 170 | $13,030 | $70 |
| Special stained specimen slides to identify organisms including interpretation and report | 296 | $11,698 | $23 |
See all 23 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,827 | $93,618 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 306 | $18,104 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 419 | $17,438 | $30 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 170 | $13,030 | $70 |
| Special stained specimen slides to identify organisms including interpretation and report | 296 | $11,698 | $23 |
| Return visit (30+ min) | 88 | $10,196 | $80 |
| Microscopic genetic analysis of tumor, manual | 72 | $9,380 | $36 |
| Antibody evaluation, each additional single antibody stain procedure | 61 | $6,747 | $26 |
| Short return visit (20+ min) | 71 | $3,947 | $48 |
| Pathology examination of tissue using a microscope, moderately high complexity | 36 | $3,430 | $73 |
| New patient visit (30+ min) | 40 | $2,710 | $68 |
| Destruction of precancer skin growth, 1 growth | 44 | $2,573 | $49 |
| Antibody evaluation, initial single antibody stain procedure | 61 | $2,065 | $32 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 20 | $1,609 | $77 |
| Pathology examination of tissue using a microscope, moderately low complexity | 153 | $1,587 | $10 |
| Biopsy of related skin growth, first growth | 49 | $1,340 | $25 |
| Return visit (30+ min) | 13 | $1,207 | $93 |
| Genetic sequencing localization, initial procedure | 20 | $924 | $38 |
| Genetic sequencing localization, each additional procedure | 12 | $636 | $30 |
| New patient visit (15+ min) | 19 | $596 | $31 |
| Biopsy of related skin growth, each additional growth | 19 | $440 | $18 |
| Special stained specimen slides to examine tissue including interpretation and report | 22 | $301 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $207 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 240 | More than 81% of doctors who do this |
| Skin biopsy | 124 | More than 78% of doctors who do this |
Who their Medicare patients are
2,274 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 45% · Also on Medicaid 12% · Health risk score 1.39. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 67% · Coronary heart disease 26% · Chronic kidney disease 24% · Diabetes 21% · Cancer 20% · Atrial fibrillation 20% · Heart failure 15% · Depression 15% · COPD 10% · Stroke 8% · Dementia 6%.
The office billed $2,515,593, Medicare allowed $274,498 and paid $208,201; for 6,431 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,274 | 6,431 | 76 | 1.39 | $2,515,593 | $208,201 |
| 2023 | 2,117 | 5,995 | 76 | 1.36 | $2,092,986 | $194,300 |
| 2022 | 1,875 | 5,258 | 76 | 1.32 | $1,508,483 | $174,006 |
| 2021 | 1,798 | 4,963 | 76 | 1.38 | $963,849 | $167,674 |
| 2020 | 1,363 | 4,125 | 75 | 1.45 | $788,041 | $140,963 |
| 2019 | 1,670 | 4,990 | 75 | 1.44 | $880,532 | $167,638 |
| 2018 | 1,543 | 4,216 | 75 | 1.40 | $734,645 | $141,517 |
| 2017 | 1,310 | 3,480 | 75 | 1.39 | $614,038 | $119,252 |
| 2016 | 1,037 | 2,671 | 75 | 1.43 | $465,333 | $91,823 |
| 2015 | 1,134 | 3,104 | 75 | 1.27 | $543,336 | $106,228 |
| 2014 | 277 | 616 | 73 | 1.34 | $103,695 | $19,439 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,698 | $90,676 | $32 |
| Special stained specimen slides to examine tissue, initial procedure | 388 | $16,712 | $31 |
| Special stained specimen slides to examine tissue, each additional procedure | 277 | $16,210 | $26 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 176 | $14,289 | $75 |
| Special stained specimen slides to identify organisms including interpretation and report | 261 | $11,454 | $24 |
| Microscopic genetic analysis of tumor, manual | 52 | $7,235 | $39 |
| Return visit (30+ min) | 68 | $6,981 | $78 |
| Antibody evaluation, each additional single antibody stain procedure | 57 | $6,273 | $26 |
| Short return visit (20+ min) | 61 | $4,064 | $53 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,855 | $47 |
| Pathology examination of tissue using a microscope, moderately high complexity | 19 | $2,464 | $77 |
| New patient visit (30+ min) | 34 | $2,348 | $69 |
| Antibody evaluation, initial single antibody stain procedure | 57 | $2,032 | $33 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 20 | $1,713 | $82 |
| Pathology examination of tissue using a microscope, moderately low complexity | 129 | $1,441 | $10 |
| Biopsy of related skin growth, first growth | 35 | $1,046 | $26 |
| Genetic sequencing localization, initial procedure | 20 | $804 | $38 |
| New patient visit (15+ min) | 15 | $554 | $37 |
| Punch biopsy, first skin growth | 11 | $479 | $40 |
| Biopsy of related skin growth, each additional growth | 12 | $425 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 19 | $278 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $237 | $2 |
2022: 22 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,558 | $84,245 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 227 | $17,841 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 317 | $13,455 | $32 |
| Special stained specimen slides to identify organisms including interpretation and report | 201 | $8,730 | $24 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 95 | $7,604 | $78 |
| Antibody evaluation, each additional single antibody stain procedure | 55 | $6,368 | $27 |
| Return visit (30+ min) | 54 | $6,015 | $79 |
| Microscopic genetic analysis of tumor, manual | 38 | $5,329 | $39 |
| Short return visit (20+ min) | 62 | $3,735 | $49 |
| Pathology examination of tissue using a microscope, moderately high complexity | 23 | $3,172 | $77 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 32 | $2,517 | $79 |
| Destruction of precancer skin growth, 1 growth | 48 | $2,384 | $40 |
| Antibody evaluation, initial single antibody stain procedure | 55 | $2,021 | $34 |
| New patient visit (30+ min) | 23 | $1,634 | $71 |
| Pathology examination of tissue using a microscope, moderately low complexity | 91 | $979 | $10 |
| Genetic sequencing localization, initial procedure | 21 | $937 | $41 |
| Biopsy of related skin growth, first growth | 30 | $779 | $24 |
| New patient visit (15+ min) | 15 | $493 | $33 |
| Short return visit | 14 | $432 | $27 |
| Punch biopsy, first skin growth | 13 | $374 | $29 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $270 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $207 | $2 |
2021: 22 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,480 | $80,642 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 196 | $13,643 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 300 | $13,277 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 138 | $10,764 | $76 |
| Special stained specimen slides to identify organisms including interpretation and report | 210 | $8,813 | $25 |
| Antibody evaluation, each additional single antibody stain procedure | 51 | $5,597 | $27 |
| Short return visit (20+ min) | 77 | $5,127 | $54 |
| Return visit (30+ min) | 38 | $4,661 | $88 |
| Microscopic genetic analysis of tumor, manual | 36 | $4,366 | $40 |
| Pathology examination of tissue using a microscope, moderately high complexity | 27 | $3,568 | $79 |
| Destruction of precancer skin growth, 1 growth | 50 | $3,000 | $48 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,725 | $83 |
| Antibody evaluation, initial single antibody stain procedure | 51 | $1,887 | $33 |
| Biopsy of related skin growth, first growth | 41 | $1,151 | $26 |
| New patient visit (30+ min) | 14 | $986 | $70 |
| Pathology examination of tissue using a microscope, moderately low complexity | 90 | $984 | $10 |
| Genetic sequencing localization, initial procedure | 14 | $622 | $41 |
| Biopsy of related skin growth, each additional growth | 14 | $458 | $18 |
| Short return visit | 16 | $433 | $27 |
| New patient visit (15+ min) | 12 | $412 | $34 |
| Special stained specimen slides to examine tissue including interpretation and report | 17 | $275 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $251 | $2 |
2020: 25 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,068 | $60,683 | $35 |
| Special stained specimen slides to examine tissue, initial procedure | 297 | $13,283 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 168 | $11,867 | $27 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 100 | $8,389 | $78 |
| Special stained specimen slides to identify organisms including interpretation and report | 174 | $8,164 | $26 |
| Antibody evaluation, each additional single antibody stain procedure | 63 | $6,935 | $28 |
| Microscopic genetic analysis of tumor, manual | 46 | $6,933 | $41 |
| Return visit (30+ min) | 57 | $3,894 | $63 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 33 | $2,830 | $83 |
| Antibody evaluation, initial single antibody stain procedure | 63 | $2,250 | $35 |
| Return visit (30+ min) | 25 | $1,893 | $73 |
| Pathology examination of tissue using a microscope, moderately high complexity | 17 | $1,840 | $80 |
| Short return visit (20+ min) | 35 | $1,602 | $43 |
| Destruction of precancer skin growth, 1 growth | 33 | $1,430 | $42 |
| Destruction of precancer skin growth, 1 growth | 16 | $828 | $52 |
| Short return visit (20+ min) | 22 | $786 | $36 |
| Pathology examination of tissue using a microscope, moderately low complexity | 55 | $596 | $10 |
| Genetic sequencing localization, initial procedure | 11 | $559 | $43 |
| Biopsy of related skin growth, first growth | 23 | $538 | $22 |
| New patient visit (15+ min) | 12 | $509 | $42 |
| Biopsy of related skin growth, first growth | 17 | $478 | $28 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $377 | $12 |
| Short return visit | 11 | $327 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $133 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 12 | $77 | $2 |
2019: 21 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,353 | $76,517 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 173 | $14,697 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 317 | $14,396 | $33 |
| Special stained specimen slides to identify organisms including interpretation and report | 238 | $11,306 | $24 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 125 | $10,011 | $75 |
| Return visit (30+ min) | 85 | $8,965 | $66 |
| Antibody evaluation, each additional single antibody stain procedure | 56 | $6,293 | $27 |
| Microscopic genetic analysis of tumor, manual | 46 | $4,100 | $41 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 42 | $3,620 | $82 |
| Destruction of precancer skin growth, 1 growth | 49 | $2,989 | $45 |
| Pathology examination of tissue using a microscope, moderately high complexity | 21 | $2,403 | $78 |
| Antibody evaluation, initial single antibody stain procedure | 59 | $2,171 | $34 |
| New patient visit (30+ min) | 28 | $1,714 | $61 |
| Biopsy of related skin growth, first growth | 38 | $1,144 | $27 |
| Pathology examination of tissue using a microscope, moderately low complexity | 75 | $899 | $10 |
| Genetic sequencing localization, initial procedure | 20 | $880 | $40 |
| New patient visit (15+ min) | 16 | $605 | $38 |
| Short return visit (20+ min) | 11 | $604 | $46 |
| Genetic sequencing localization, each additional procedure | 12 | $513 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $343 | $2 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $286 | $10 |
2018: 23 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,235 | $68,662 | $33 |
| Special stained specimen slides to examine tissue, initial procedure | 277 | $11,123 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 127 | $9,806 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 133 | $9,720 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 166 | $8,643 | $24 |
| Return visit (30+ min) | 79 | $6,244 | $60 |
| Antibody evaluation, each additional single antibody stain procedure | 39 | $4,241 | $26 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 36 | $2,872 | $80 |
| Pathology examination of tissue using a microscope, moderately high complexity | 16 | $2,638 | $78 |
| Return visit (30+ min) | 33 | $2,330 | $69 |
| Destruction of precancer skin growth, 1 growth | 36 | $1,945 | $43 |
| Microscopic genetic analysis of tumor, manual | 25 | $1,861 | $41 |
| Antibody evaluation, initial single antibody stain procedure | 41 | $1,427 | $32 |
| New patient visit (30+ min) | 22 | $1,409 | $64 |
| Biopsy of single growth of skin and/or tissue | 38 | $1,207 | $29 |
| Destruction of precancer skin growth, 1 growth | 18 | $888 | $49 |
| Pathology examination of tissue using a microscope, moderately low complexity | 67 | $690 | $10 |
| Genetic sequencing localization, initial procedure | 12 | $489 | $41 |
| New patient visit (15+ min) | 11 | $484 | $44 |
| Biopsy of single growth of skin and/or tissue | 12 | $434 | $36 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $397 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $162 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $93 | $2 |
2017: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,045 | $56,937 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 266 | $11,203 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 119 | $9,161 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 150 | $6,788 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 86 | $6,544 | $75 |
| Return visit (30+ min) | 62 | $5,678 | $59 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 44 | $3,483 | $79 |
| Antibody evaluation, each additional single antibody stain procedure | 33 | $3,333 | $26 |
| Pathology examination of tissue using a microscope, moderately high complexity | 15 | $2,957 | $78 |
| Destruction of precancer skin growth, 1 growth | 34 | $2,122 | $43 |
| New patient visit (30+ min) | 33 | $2,041 | $62 |
| Microscopic genetic analysis of tumor, manual | 17 | $1,718 | $51 |
| Antibody evaluation, initial single antibody stain procedure | 33 | $1,138 | $33 |
| Biopsy of single growth of skin and/or tissue | 37 | $1,131 | $28 |
| Pathology examination of tissue using a microscope, moderately low complexity | 52 | $598 | $10 |
| Short return visit (20+ min) | 13 | $576 | $44 |
| New patient visit (15+ min) | 15 | $571 | $38 |
| Biopsy of each additional growth of skin and/or tissue | 12 | $337 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $197 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $146 | $2 |
2016: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 789 | $40,146 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 96 | $7,633 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 171 | $6,832 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 68 | $6,166 | $25 |
| Return visit (30+ min) | 61 | $5,953 | $64 |
| Special stained specimen slides to identify organisms including interpretation and report | 130 | $4,784 | $24 |
| Antibody evaluation, each additional single antibody stain procedure | 26 | $2,721 | $25 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 32 | $2,507 | $78 |
| New patient visit (30+ min) | 38 | $2,290 | $60 |
| Destruction of precancer skin growth, 1 growth | 33 | $2,256 | $48 |
| Microscopic genetic analysis of tumor, manual | 25 | $1,844 | $51 |
| Biopsy of single growth of skin and/or tissue | 36 | $1,473 | $32 |
| Antibody evaluation, initial single antibody stain procedure | 27 | $1,002 | $33 |
| Short return visit (20+ min) | 18 | $866 | $43 |
| New patient visit (15+ min) | 16 | $717 | $45 |
| Pathology examination of tissue using a microscope, moderately low complexity | 52 | $546 | $9 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $363 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $167 | $2 |
2015: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 858 | $46,005 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 125 | $9,536 | $73 |
| Special stained specimen slides to examine tissue, initial procedure | 215 | $8,512 | $32 |
| Special stained specimen slides to identify organisms including interpretation and report | 171 | $6,855 | $25 |
| Special stained specimen slides to examine tissue, each additional procedure | 92 | $6,828 | $20 |
| Antibody evaluation, initial single antibody stain procedure | 28 | $6,030 | $39 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 43 | $3,251 | $74 |
| New patient visit (30+ min) | 49 | $3,087 | $63 |
| Return visit (30+ min) | 26 | $2,291 | $67 |
| Microscopic genetic analysis of tumor, manual | 25 | $2,218 | $50 |
| Biopsy of single growth of skin and/or tissue | 41 | $1,610 | $34 |
| Destruction of precancer skin growth, 1 growth | 27 | $1,565 | $45 |
| Short return visit (20+ min) | 19 | $829 | $41 |
| Genetic sequencing localization, initial procedure | 14 | $691 | $41 |
| Pathology examination of tissue using a microscope, moderately low complexity | 62 | $671 | $10 |
| New patient visit (15+ min) | 16 | $627 | $39 |
| Short return visit | 17 | $477 | $23 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $260 | $11 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $248 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $122 | $2 |
2014: 6 services
| Pathology examination of tissue using a microscope, intermediate complexity | 232 | $11,818 | $34 |
| Special stained specimen slides to identify organisms including interpretation and report | 47 | $1,739 | $25 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 52 | $1,598 | $28 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 14 | $1,142 | $76 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 28 | $639 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 21 | $232 | $10 |
Medicaid work
$31,725 in 2024
Medicaid paid $31,725 for 880 billed services this clinician did in 2024, up to 88 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 568 | $20,672 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 185 | $5,613 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 85 | $4,327 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 22 | $743 |
| TISSUE EXAM BY PATHOLOGIST | 20 | $370 |
| 2024 | 880 | 5 | 88 | $31,725 |
| 2023 | 939 | 5 | 88 | $33,760 |
| 2022 | 462 | 3 | 51 | $16,294 |
| 2021 | 519 | 3 | 47 | $17,995 |
| 2020 | 304 | 3 | 39 | $11,429 |
| 2019 | 406 | 3 | 45 | $12,912 |
| 2018 | 332 | 2 | 39 | $12,919 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 588 | $22,747 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 159 | $4,997 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 108 | $3,867 |
| TISSUE EXAM BY PATHOLOGIST | 44 | $1,156 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 40 | $993 |
2022
| TISSUE EXAM BY PATHOLOGIST | 373 | $12,967 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 55 | $1,980 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 34 | $1,348 |
2021
| TISSUE EXAM BY PATHOLOGIST | 394 | $13,110 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 107 | $4,257 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 18 | $628 |
2020
| TISSUE EXAM BY PATHOLOGIST | 253 | $9,102 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 38 | $1,992 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $335 |
2019
| TISSUE EXAM BY PATHOLOGIST | 355 | $11,239 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 25 | $921 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 26 | $753 |
2018
| TISSUE EXAM BY PATHOLOGIST | 308 | $11,741 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 24 | $1,178 |
Drugs they prescribed that Part D paid
$164,586
Pharmacies billed $164,586 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 367) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
334 generic and 33 brand-name prescriptions · $164,586 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tacrolimus | 16 | $2,926 | $183 |
| Clobetasol Propionate | 24 | $1,320 | $55 |
| Calcipotriene | 12 | $1,282 | $107 |
| Desonide | 16 | $1,204 | $75 |
| Fluorouracil | 14 | $1,009 | $72 |
See all 11 drugs
| Tacrolimus | 16 | $2,926 | $183 |
| Clobetasol Propionate | 24 | $1,320 | $55 |
| Calcipotriene | 12 | $1,282 | $107 |
| Desonide | 16 | $1,204 | $75 |
| Fluorouracil | 14 | $1,009 | $72 |
| Doxycycline Hyclate | 12 | $970 | $81 |
| Fluocinonide | 24 | $854 | $36 |
| Metronidazole | 18 | $843 | $47 |
| Ketoconazole | 52 | $647 | $12 |
| Minoxidil | 25 | $381 | $15 |
| Triamcinolone Acetonide | 26 | $202 | $8 |
Year by year
| 2024 | 367 | 99 | 0% (0) | 9% | $164,586 |
| 2023 | 297 | 88 | 0% (0) | None | $140,883 |
| 2022 | 335 | 78 | 0% (0) | 10% | $91,398 |
| 2021 | 307 | 83 | 0% (0) | 10% | $129,535 |
| 2020 | 218 | 72 | 0% (0) | 10% | $40,671 |
| 2019 | 167 | 55 | 0% (0) | 12% | $9,916 |
| 2018 | 198 | 64 | 0% (0) | 8% | $22,591 |
| 2017 | 146 | 54 | 0% (0) | 12% | $11,773 |
| 2016 | 162 | 55 | 0% (0) | 17% | $15,945 |
| 2015 | 96 | 36 | None | 23% | $7,849 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Fluocinonide | 34 | $1,895 | $56 |
| Clobetasol Propionate | 16 | $1,666 | $104 |
| Tacrolimus | 11 | $1,086 | $99 |
| Doxycycline Hyclate | 11 | $1,001 | $91 |
| Desonide | 11 | $896 | $81 |
| Ketoconazole | 42 | $812 | $19 |
| Clotrimazole | 17 | $244 | $14 |
| Triamcinolone Acetonide | 20 | $220 | $11 |
| Hydrocortisone | 14 | $78 | $6 |
2022: 11 drugs
| Jublia | 11 | $8,026 | $730 |
| Fluocinonide | 44 | $2,694 | $61 |
| Calcipotriene | 14 | $2,043 | $146 |
| Fluorouracil | 13 | $1,450 | $112 |
| Ketoconazole | 53 | $1,097 | $21 |
| Ciclopirox | 14 | $1,061 | $76 |
| Desonide | 13 | $1,032 | $79 |
| Clotrimazole | 22 | $520 | $24 |
| Triamcinolone Acetonide | 25 | $319 | $13 |
| Mupirocin | 13 | $259 | $20 |
| Gabapentin | 20 | $170 | $8 |
2021: 10 drugs
| Fluocinonide | 39 | $2,143 | $55 |
| Calcipotriene | 13 | $1,944 | $150 |
| Clobetasol Propionate | 15 | $1,371 | $91 |
| Ketoconazole | 48 | $848 | $18 |
| Ciclopirox | 11 | $355 | $32 |
| Mupirocin | 13 | $227 | $17 |
| Triamcinolone Acetonide | 21 | $185 | $9 |
| Gabapentin | 16 | $185 | $12 |
| Clotrimazole | 14 | $139 | $10 |
| Hydrocortisone | 20 | $85 | $4 |
2020: 5 drugs
| Fluorouracil | 18 | $1,831 | $102 |
| Clobetasol Propionate | 16 | $1,826 | $114 |
| Fluocinonide | 30 | $1,526 | $51 |
| Ketoconazole | 29 | $448 | $15 |
| Triamcinolone Acetonide | 22 | $262 | $12 |
2019: 5 drugs
| Clobetasol Propionate | 12 | $1,998 | $166 |
| Fluocinonide | 15 | $615 | $41 |
| Ketoconazole | 19 | $454 | $24 |
| Triamcinolone Acetonide | 25 | $222 | $9 |
| Nystatin | 11 | $138 | $13 |
2018: 4 drugs
| Ketoconazole | 24 | $1,368 | $57 |
| Fluocinonide | 22 | $1,045 | $48 |
| Clotrimazole | 21 | $508 | $24 |
| Triamcinolone Acetonide | 15 | $283 | $19 |
2017: 3 drugs
| Doxycycline Hyclate | 15 | $2,122 | $141 |
| Desonide | 23 | $1,669 | $73 |
| Triamcinolone Acetonide | 12 | $130 | $11 |
2016: 4 drugs
| Desonide | 22 | $3,593 | $163 |
| Fluocinonide | 15 | $1,074 | $72 |
| Ketoconazole | 28 | $809 | $29 |
| Triamcinolone Acetonide | 18 | $243 | $13 |
2015: 2 drugs
| Triamcinolone Acetonide | 16 | $354 | $22 |
| Ketoconazole | 15 | $194 | $13 |
Money from drug and device companies
$31 in 2023
| 2023 | 1 | 2 | None | $31 |
| 2020 | 1 | 1 | $2,400 | $2,400 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $31 | 2 payments
|
See all 2 published payments
| Pfizer | Education · 2023-05-10 | Cibinqo | $15 |
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
See earlier years (2020)
2020: $2,400
| Stemline Therapeutics | Elzonris | $2,400 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1326272089
- Licence
- CA A131200California A131200: Current · expires 2027-12-31
- Trained
- Harvard Medical School, 2009
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-05-11
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.